u/Variant_Invest

ResMed is one of those names where the market found a reason to sell and never came back to check if the reason was still valid. GLP-1 drugs were going to shrink the sleep apnea population. Okay, maybe eventually. But you are looking at 936 million diagnosed sleep apnea cases globally, and most people with the condition are nowhere near a Wegovy prescription. The addressable market is not going away on any reasonable timeline.

What actually makes ResMed worth owning is the consumables. The masks, the tubes, the headgear — patients replace these every 90 days whether they feel like it or not, because their insurance covers it on a schedule. That segment runs gross margins well above 60% and it compounds quietly every quarter. You cannot disrupt it with a drug because the device is treating an anatomical problem, and even GLP-1 patients who lose weight still often need CPAP for residual apnea.

The data platform is the part everyone skips. ResMed's AirView system is connected to something like 22 million devices. Payers love it because compliance data reduces hospitalizations. The more connected patients they have, the more valuable the platform becomes to the entire care ecosystem. That is a recurring revenue moat with no real competition.

They do about $2.2B in annual free cash flow. The stock has been treated like a melting ice cube for two years because of a pharmaceutical overhang that has not materialized in the numbers. Compliance rates have held. Revenue growth has held. The thesis was wrong and the stock has not adjusted yet.

This is a 30x-plus quality business trading at a significant discount to where it historically gets valued. The GLP-1 narrative gave people a reason to sell and an excuse not to buy back. That window does not stay open forever.

La-Z-Boy has been transitioning for years from a pure wholesale manufacturer into a company that increasingly controls its own retail stores. The core idea is simple: when you own the store, you capture both the manufacturing margin and the retail margin on the same sale. That is structurally higher earnings power than the legacy model, and consensus is not pricing it that way.

The company has been converting franchisee-operated locations into company-owned stores in key markets. What that does is swap lumpy, volume-dependent wholesale revenue for more predictable retail traffic with higher gross margins. You also get real-time customer data that feeds back into design and inventory — a compounding operational advantage that pure wholesalers do not have.

The macro setup adds some optionality. Housing turnover is near multi-decade lows, which hurts the entire furniture category. But La-Z-Boy is not competing in the commodity segment. When rates normalize and housing inventory unlocks, the pent-up replacement demand hits a company with a structurally better margin structure than the one it had heading into the last housing boom.

The balance sheet is clean — no meaningful debt — and management has been returning capital via buybacks and dividends while simultaneously funding the store buildout. That combination does not happen at companies with broken underlying economics.

Valuation: roughly 10-11x earnings, which is roughly where it traded before the retail transformation started generating real returns. The market is still pricing the old wholesale story. The actual business has been converging toward something with better returns on capital for a few years now, quietly.

Not a high-growth name. But as a value setup on an overlooked consumer brand actively improving its own economics, it deserves more attention than it gets.

Most people lump KLA in with the rest of the semi equipment names and wait for the cycle to turn. That's the wrong frame.

Process control is not optional in chipmaking. You cannot cut inspection and metrology without destroying yields, which means chip manufacturers cannot actually slow down KLA spending the way they can with CVD tools or etch equipment. KLA captures around 50% of the process control market and the next closest competitor is nowhere close to challenging that position. Customers do not switch — the switching costs are enormous because KLA's tools are embedded in process recipes across fabs that took years to qualify.

The AI angle here is real and it is not priced in. Advanced packaging, HBM stacking, and sub-2nm logic all require dramatically more inspection steps than prior nodes. Each technology transition structurally increases KLA's dollar content per wafer. This is not a cyclical tailwind — it is a step-change in how much process control intensity chipmakers need.

Margins are exceptional. Gross margins run mid-60s and the company has been buying back stock aggressively through the downcycle. They generate real free cash flow even when wafer fab equipment demand softens.

The tariff panic is hitting everything in semi equipment right now. I think that is creating an entry point in a name with a genuinely defensible position. If you are looking for a way to play the AI infrastructure buildout without the valuation risk in the pure-play GPU names, KLA deserves serious attention. Analysts who actually understand the process control market have targets running around $1840.

Not financial advice, do your own work.

AECOM is one of those names that gets lumped in with cyclical project contractors when the reality is a lot more durable than that. The backlog is at record levels, which means the revenue pipeline for the next few years is effectively locked in regardless of what macro does in the short term.

The part consensus keeps missing is the margin story. AECOM has been aggressively winding down its lower-margin, risk-heavy construction businesses and pivoting toward a pure advisory and program management model. That shift is still playing out, and the margin expansion it implies is not fully reflected in where the stock trades.

On top of that, the firm has been deploying AI tools internally for project management and estimation. That is not a marketing story — it directly reduces the headcount intensity of winning and managing large government infrastructure contracts. If you hold margins flat from here you miss the whole thesis. Model what the mix shift does over two or three years and the stock looks materially cheap.

Government infrastructure spend is also one of the few pockets of demand that does not disappear in a tariff-driven slowdown. These are multi-year programs with committed budgets. That gives AECOM a different risk profile than the market is currently pricing in.

This re-rates when the backlog converts and margins tick higher. Not a near-term trade, but the setup is genuinely underappreciated right now.

Everyone agrees Amgen faces a real exclusivity cliff. Enbrel is done, Otezla faces pressure, and the market has been pricing that for years. What I think people are getting wrong is the replacement math.

The biosimilars business is not a speculative bet at this point. Amgen already has approved products competing against some of the most expensive biologics in the market, and the manufacturing advantage they built over 40+ years is actually a serious barrier to entry. When people talk about biosimilar competition hurting Amgen, they are ignoring that Amgen is now one of the biosimilar competitors. That is a different kind of company than it was five years ago.

On the new launches, the market is treating Repatha like a disappointment that proved cardiometabolic drugs cannot scale. I think that is the wrong read. Repatha had reimbursement problems that have actually been getting better as payers have accepted outcomes data. The GLP-1 wave is drawing attention to cardiovascular risk reduction broadly, which is a tailwind for a drug that demonstrably cuts heart attack rates. The setup for the next few years looks better than consensus models.

TEZSPIRE is another one flying under the radar. Severe asthma is a large market, the biologic penetration is still relatively low, and Amgen has a commercial infrastructure that most emerging biotech does not. They can actually sell the drug.

The balance sheet is not great given the Horizon acquisition debt, but the free cash flow generation is strong enough to service it. They guided for mid-single-digit revenue growth through the decade, and the Street is discounting that like they do not believe it.

At current prices you are buying a business with legitimate clinical assets, a biosimilar platform that actually makes money, and a FCF yield that pays you to wait. I think the LOE panic is masking a pretty reasonable setup.

People have been freaking out about Microsoft capex for the past year. The argument is simple: they are spending an insane amount on AI infrastructure before the demand is proven. But there is a number the bears keep skipping — Microsoft has roughly $400B in contracted cloud and AI backlog with a short weighted duration. That means the customers already exist, the contracts are signed, and the revenue is coming in near term. This is not speculative build-out. It is capacity chasing committed demand that is already on the books.

Azure growth reaccelerated last quarter, coming in above 31% after a brief plateau. Azure AI services alone are now running at a $13B annual revenue run rate. That is not a rounding error — it is a real business within a business, and it is still early innings.

The margin compression fear is also misread. People see raw capex and assume pain forever. Datacenter depreciation spreads over decades, and once demand fills the infrastructure the operating leverage is substantial. Copilot has crossed 160M paid users. GitHub Copilot went from developer novelty to embedded in enterprise workflows fast. That is contract stickiness that compounds over time.

At roughly 27x forward earnings you are paying a premium. But for a company with $400B in near-term contracted backlog, 31%+ cloud growth reaccelerating, and a software moat that is arguably strengthening as AI embeds deeper into enterprise workflows — the premium holds up. The capex bears are looking at the wrong number entirely. The backlog is the number that matters.

GE Aerospace is not the GE you remember. The conglomerate is gone — power, healthcare, the whole mess — and what is left is a focused engine manufacturer that is transitioning into something far more valuable: a recurring data services business.

The real story here is not jet engines. It is the FLIGHT DECK platform and the long-term service agreements that come with every engine GE puts on a plane. Airlines pay GE per flight hour, for decades, for maintenance and data analytics on engines that GE owns the IP to and that competitors cannot easily replicate. These contracts have terms of 10-20 years.

Right now the market is selling this down on tariff fears. That is understandable for a company that makes physical hardware. But the services revenue — which is the dominant part of margins — is essentially immune to tariff risk. You are not importing or exporting a software subscription per flight hour.

The installed engine base is over 44,000 engines. That base generates service revenue largely regardless of whether airlines are ordering new planes. Aftermarket demand is driven by flight hours, not new aircraft deliveries. And global flight hours have been running above 2019 levels.

The backlog is enormous. The LEAP engine powers the 737 MAX and A320neo and is the dominant narrowbody engine globally. GE and CFM International have a near-monopoly on that segment for the next decade minimum.

The market is treating this like a cyclical trade in a tariff storm. The actual business is a long-duration annuity hiding inside an industrial stock. Those do not stay mispriced forever.

When Ozempic and Wegovy started dominating headlines, the market decided DexCom was collateral damage. The logic was: fewer diabetics need insulin, therefore fewer diabetics need CGMs. That thesis was wrong then and it is still wrong.

Type 2 diabetics on GLP-1s still need glucose monitoring. The drugs reduce A1C but they do not eliminate hypoglycemia risk, especially in patients who are also on insulin. And the Type 1 market — which is DexCom's highest-value segment — has nothing to do with GLP-1s at all. T1D is autoimmune. Ozempic does not change that.

What actually happened during the selloff is that the market conflated a legitimate competitive concern (Abbott's Libre gaining share) with an existential threat (GLP-1s making CGM obsolete). Those are two very different problems. The first is a margin and pricing story. The second was mostly fear.

The part of this that is genuinely underpriced right now is the cash flow inflection. DexCom spent years building out manufacturing capacity and its sales force. That capex cycle is largely done. The company is now at a point where revenue can grow without a corresponding jump in costs. Operating leverage is starting to show up. Free cash flow as a percentage of revenue has been climbing.

Meanwhile, CGM penetration globally is still in the single digits for eligible patients. The U.S. is more penetrated, but international is a long runway. The G7 15-day sensor is the most accurate product on the market and it expands wear time meaningfully.

I am not saying this is a screaming buy right now — the valuation requires growth to materialize. But the market is pricing it like Abbott wins everything and GLP-1s eat the rest. That framing is too pessimistic and ignores what the actual financials are starting to show.

Wendy's has been in the penalty box for about a year now and the narrative has calcified: traffic is down, comps are ugly, the breakfast push never really worked. I get it. But there is a difference between a company with a broken business model and one that executed poorly for a few quarters. Wendy's is the latter.

The actual business is royalty income from ~7,000 franchise locations. Wendy's owns almost none of its restaurants. That means when a franchisee has a bad year, it flows through as lower royalty dollars — but the cost base barely moves. It is an asset-light structure that most people understand in theory but keep forgetting about in practice when they look at the same-store sales headline.

The US sales reset was mostly self-inflicted: they pushed value messaging too hard, confused the brand positioning, and lost some of the premium perception that differentiated them from McDonald's and Burger King. That is fixable. Brian Niccol showed at Chipotle what a focused operator can do to a consumer brand that lost its way. Wendy's has the franchisee economics to support a recovery — the question is execution.

International is also being ignored. The UK and Canada businesses have been growing, and there is real unit expansion happening outside the US. That does not show up in the comp number everyone watches.

At the current multiple, you are basically paying trough-cycle prices for a royalty stream on a globally recognized fast food brand with 70+ years of brand equity. If they get the US positioning right — and the new menu simplification efforts suggest they are at least pointed in the right direction — the earnings recovery is meaningful.

This is not a complicated thesis. It is a franchise business temporarily impaired by its own execution mistakes, priced like the impairment is permanent.

Most people who own Vertex understand the cystic fibrosis business. Trikafta has an ~80% patient penetration in eligible CF patients in the US and basically operates as a monopoly with no meaningful competitive threat. It generates roughly $9B in annual revenue off margins that most pharma companies can only dream about.

What the market underprices is Vertex's actual platform — not just the drug, but how they found it. Their approach is to identify rare diseases where the genetic cause is well understood, then build a small molecule that corrects the underlying defect. CF was proof of concept. Pain (VX-548) is the next in line and it's showing up in the numbers already.

VX-548 got FDA approval for acute pain and the early commercial ramp is real. More importantly it's opioid-free, which changes the prescriber conversation entirely. Hospitals and physicians have been burned by opioid liabilities for a decade — an effective non-addictive alternative gets a different kind of reception than a typical drug launch.

Beyond that, their APOL1-mediated kidney disease program (inaxaplin) and the gene editing work with CRISPR Therapeutics on sickle cell (Casgevy) add optionality that consensus models barely touch. Casgevy is a one-time cure. The pricing power on that is genuinely different from anything in pharma.

The CF revenue stream alone probably justifies a fair chunk of the current valuation. But when you layer on a pain franchise that is actually gaining traction, a kidney disease candidate with a massive addressable population, and the optionality of more rare disease programs, the market is basically pricing in nothing from the pipeline.

Vertex has $9B in cash and zero debt. They do not need to raise capital, dilute shareholders, or take on partnership risk to fund development. That financial position matters more than people acknowledge — most biotech companies are burning cash to build what Vertex already has.

It trades at a premium to pharma peers but the premium is not as large as it looks once you adjust for balance sheet strength, margin profile, and pipeline optionality. Not a screaming buy at current prices but if you think the pain launch continues and the kidney program reads out well, the multiple looks different.

Most of the Marvell coverage right now is focused on the AI custom silicon opportunity. I get it — the hyperscaler relationships are real and the design wins are not fake. But the actual FY26 financials are messier than the narrative suggests, and the market is being too generous.

The margin improvement that everyone keeps citing was partially driven by the automotive Ethernet divestiture — a one-time asset sale that boosted reported numbers but does not reflect ongoing operating performance. Strip that out and the picture changes. Operating cash flow has been lagging reported EPS, which is the kind of divergence that usually means something.

Inventory also climbed to over $1 billion during a period when the company is supposed to be riding a clean AI-driven demand wave. That is not consistent with a business firing on all cylinders. If AI demand is as strong as the sell-side thinks, inventory should be moving, not building.

Then there is valuation. At current levels, Marvell is pricing in execution that leaves almost no room for error — in a semiconductor market where the broader cycle has not fully normalized. The AI ASIC revenue is real, but it is concentrated in a small number of hyperscaler relationships, and customer concentration risk rarely gets priced in until it becomes a problem.

Not saying the story is broken. Saying the risk/reward is worse than it looks, and the FY26 results are not as clean as the headlines suggest.

Target has had a rough couple of years. Inventory miscalculations post-COVID, a pullback in discretionary spending, margin compression from markdowns. The stock went from $260 to under $100 and a lot of people declared it dead. I think that reads the situation wrong.

The core of the Target business is actually intact. The store footprint is well-located, the owned brands still command real loyalty, and the fulfillment infrastructure they built during COVID — same-day delivery, drive-up, ship-from-store — has become a genuine competitive asset. These are not things you build overnight and they are not cheap to replicate.

What happened was a sequence of execution mistakes layered on top of a consumer slowdown in discretionary categories. Those are real problems. But they are solvable operational problems, not structural ones. Walmart had its own version of this in the early 2010s and came out the other side. Target has the brand equity and the balance sheet to do the same thing.

The valuation today is pricing in a scenario where the margin recovery never happens. If they get back to even 6-7% operating margins — which is below their historical range — the stock is trading at a significant discount to intrinsic value at current prices. The Street keeps cutting estimates every quarter, which creates the setup for positive surprises as comps stabilize.

I am not saying this happens fast. But at this valuation, you are being paid well to wait for a business that still has real competitive advantages. The thesis is simple: this is not Sears. It is Target, and it has the tools to fix what went wrong.

Most people group KLA in with the other semi equipment names and assume they all move together with the cycle. That framing misses what KLA actually does.

KLA's business is process control — the inspection and metrology systems that tell chipmakers whether their fabrication process is working. Unlike deposition or etch tools, you cannot skip this step. If you are running a leading-edge node and your yield is off, you are losing millions of dollars a day. KLA is how fabs figure out what went wrong.

That dynamic means KLA holds its ground better than peers in down cycles. Their services revenue is also substantial — fabs keep running installed equipment and paying for support even when new capex gets cut. The recurring portion of revenue is bigger than most people model.

The bigger misunderstanding is what AI does to their business. Advanced packaging — HBM, chiplets, CoWoS — requires an inspection intensity that is completely different from traditional nodes. Every additional interconnect layer needs to be verified. KLA dominates this space and the ramp is still early. Process control as a share of total wafer fab equipment spend has been rising for years and shows no sign of stopping.

They also have pricing power that rarely gets discussed. They are not competing on price with ASML or Lam. They are selling fabs a service worth multiples of the tool cost in avoided yield loss.

The stock has gotten dragged down with the tariff selloff but KLAC revenue in Korea and Taiwan is tied to long-term committed fab roadmaps, not discretionary budgets. That distinction matters and the market is not making it.

Most people writing off Danaher right now are focused on the biotools softness after the COVID pull-forward unwound. That part is fair — life sciences capex got crushed and Danaher felt it more than most because they were so levered to that cycle. But that framing completely ignores what makes Danaher different from any other medtech or diagnostics roll-up.

The thing most people skip over is the Danaher Business System. DBS is an internal operating philosophy — lean tools, kaizen, continuous improvement baked into every acquisition they make. It's not just a slogan. Danaher has spent 30+ years using it to expand margins at every company they buy. That system doesn't break during a soft patch. It keeps running.

The Biotechnology segment (formerly Life Sciences) is where consensus is anchored, and it's where the noise is. But the Diagnostics segment — which includes Beckman Coulter, Cepheid, and Radiometer — throws off extremely durable recurring revenue tied to hospital lab workflows that aren't discretionary. Hospitals don't stop running CBC panels because rates are high.

The spinoff of Veralto in late 2023 actually cleaned things up. What's left is a more focused company with two high-quality segments and a management team that has compounded returns through every cycle since the 1980s. Post-spinoff Danaher is trading like the old conglomerate discount still applies. It doesn't.

The consensus bear case is basically: biotools recovery is slow and the multiple is too high for where we are in the cycle. My view is the opposite — you're getting the DBS machine at a trough earnings point, and whoever is patient enough to hold through the recovery is buying a compounder that will look very different in 24 months. The recurring revenue base in Diagnostics alone justifies a lot of the current price, and the biotech recovery isn't a question of if, it's when.